<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291014</url>
  </required_header>
  <id_info>
    <org_study_id>NN110 1U01NS114001</org_study_id>
    <nct_id>NCT04291014</nct_id>
  </id_info>
  <brief_title>Light Therapy for PD - Dose Selection</brief_title>
  <official_title>A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the most effective dose of light therapy to improve sleep in&#xD;
      people with Parkinson's Disease. Four groups of participants will receive bright-white or&#xD;
      dim-red light therapy at different times throughout the day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 16-week, randomized, phase II, parallel-group, dose-selection clinical trial of LT&#xD;
      in participants with PD and co-existing sleep disruption using a comparative selection trial&#xD;
      design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a 16-week, randomized, phase II, parallel-group, dose-selection clinical trial of LT in participants with PD and co-existing sleep disruption using a comparative selection trial design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PDSS-2</measure>
    <time_frame>8 weeks</time_frame>
    <description>The PDSS-2 is a 15-question instrument designed to simultaneously capture the multidimensional aspects of sleep-related problems and changes in sleep quality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS-16</measure>
    <time_frame>8 weeks</time_frame>
    <description>The PFS-16 is a patient-rated scale that measures fatigue. The scale allows the measurements of the presence of fatigue (seven items) and its impact on daily function (nine items).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Sleep Disorder</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>BWLT once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive bright white light therapy daily once a day (in the evening)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BWLT twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BWLT weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive bright white light therapy once weekly (in the evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRLT twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive dim red light twice daily (morning and evening).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SunRay Light Boxes</intervention_name>
    <description>SunRay light boxes will be used to administer the light therapy.</description>
    <arm_group_label>BWLT once daily</arm_group_label>
    <arm_group_label>BWLT twice daily</arm_group_label>
    <arm_group_label>BWLT weekly</arm_group_label>
    <arm_group_label>DRLT twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of idiopathic PD as defined by the Movement Disorder Society Clinical&#xD;
             Diagnostic Criteria for Parkinson's disease;&#xD;
&#xD;
          2. PD Hoehn and Yahr stage 2-4;&#xD;
&#xD;
          3. A score of 2 (mild) or above on the Sleep Problems question of the MDS-UPDRS Part 1;&#xD;
&#xD;
          4. Stable dose of all PD medications for at least 30 days prior to randomization;&#xD;
&#xD;
          5. Willingness to wear an Actiwatch and complete daily sleep logs;&#xD;
&#xD;
          6. Age 45 or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Atypical or secondary forms of parkinsonism;&#xD;
&#xD;
          2. Co-existent significant sleep apnea at screening, as determined by the PI's clinical&#xD;
             assessment; adequately treated sleep apnea, as assessed by sleep apnea machine&#xD;
             download (CPAP download) will be permitted;&#xD;
&#xD;
          3. Co-existent symptomatic restless legs syndrome (RLS) (as assessed by the International&#xD;
             Classification of Sleep Disorders (ICDS) diagnostic criteria for RLS) at screening;&#xD;
&#xD;
          4. Cognitive impairment as determined by a Mini Mental State Examination score &lt;25 at&#xD;
             screening;&#xD;
&#xD;
          5. Presence of moderate depression defined as a Beck Depression Inventory II (BDI-II)&#xD;
             score ≥20 at screening;&#xD;
&#xD;
          6. Current untreated hallucinations or psychosis (drug-induced or spontaneous) with a&#xD;
             score of 2 or above on the Hallucinations and Psychosis question of the MDS-UPDRS Part&#xD;
             2;&#xD;
&#xD;
          7. Use of hypno-sedative drugs for sleep or stimulants, unless the participant has been&#xD;
             on a stable dose for at least 60 days prior to the screening;&#xD;
&#xD;
          8. Ongoing or recent (within 30 days prior to screening) Cognitive Behavioral Therapy for&#xD;
             Insomnia;&#xD;
&#xD;
          9. Use of antidepressants, unless the participant has been on a stable dose for at least&#xD;
             60 days prior to the screening;&#xD;
&#xD;
         10. Work hours between 10 PM and 6 AM, within 60 days prior to randomization or&#xD;
             anticipated during the 16 weeks after screening;&#xD;
&#xD;
         11. Travel between 3 or more time zones within 45 days prior to study screening or&#xD;
             anticipated such travel during the 16 weeks after screening;&#xD;
&#xD;
         12. Unstable or serious medical illness;&#xD;
&#xD;
         13. History of significant eye trauma or disease, retinopathy, or cataract Grade 4 that&#xD;
             would significantly affect transmission or processing of light through either eye;&#xD;
&#xD;
         14. Current use, use at any time during study participation, or use within the 30 days&#xD;
             prior to screening of photosensitizing or other medications that in the opinion of the&#xD;
             investigator would interfere with the safety of the participant during the trial,&#xD;
             including: amiodarone, porfimer, psoralens, chlorpromazine, quinidine, demeclocycline,&#xD;
             temoporfin, tetracycline, fleroxacin, oral isoretinoin, voriconazole, nalidixic acid,&#xD;
             thioridazine, St. John's wort, ofloxacin, and piroxicam;&#xD;
&#xD;
         15. Pregnant women will be excluded from participation; if a participant is&#xD;
             pre-menopausal, a urine pregnancy test will be conducted at randomization to determine&#xD;
             eligibility.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleksandar Videnovic, MD</last_name>
    <phone>617-724-3837</phone>
    <email>AVIDENOVIC@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Murphy</last_name>
    <phone>617-724-2644</phone>
    <email>samantha.murphy@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Benge</last_name>
      <phone>205-975-0445</phone>
      <email>mabenge@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilia Andrews</last_name>
      <phone>602-406-4206</phone>
      <email>Giulia.Andrews@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yessica Landaverde</last_name>
      <phone>949-824-7524</phone>
      <email>yylandav@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poonam Prasad</last_name>
      <phone>916-734-5057</phone>
      <email>psprasad@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Paquette</last_name>
      <phone>203-785-2577</phone>
      <email>Danielle.paquette@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Vargas Parra</last_name>
      <phone>305-243-3647</phone>
      <email>s.vargasparra@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Szela</last_name>
      <phone>312-503-2593</phone>
      <email>monika.szela@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loraine Brenner</last_name>
      <phone>319-356-4361</phone>
      <email>loraine-brenner@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Bwala</last_name>
      <phone>617-643-0654</phone>
      <email>GBWALA@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vasiliki Patsiogiannis</last_name>
      <phone>617-726-6552</phone>
      <email>VPATSIOGIANNIS@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilda Gutierrez</last_name>
      <phone>617-667-3086</phone>
      <email>hgutier1@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Rasnake</last_name>
      <phone>734-232-2452</phone>
      <email>arasnake@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ammel</last_name>
      <phone>314-747-3470</phone>
      <email>ammelm@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Auerbach</last_name>
      <phone>212-746-2474</phone>
      <email>Gra2012@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Lopez</last_name>
      <phone>212-241-9038</phone>
      <email>mindy.lopez1@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Guerrero</last_name>
      <email>Nicole_Guerrero@URMC.Rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Stonybrook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Lamb</last_name>
      <phone>631-444-8068</phone>
      <email>Jessica.Lamb@stonybrook.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Blystone</last_name>
      <phone>315-464-9756</phone>
      <email>blystone@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Burgos Aguilar</last_name>
      <phone>336-713-2603</phone>
      <email>caguilar@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Molloy</last_name>
      <phone>513-558-7118</phone>
      <email>angela.molloy@uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Ambrogi</last_name>
      <phone>614-688-6685</phone>
      <email>Katherine.ambrogi@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Levine</last_name>
      <phone>215-829-5136</phone>
      <email>Sarah.levine@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beth Harders</last_name>
      <phone>267-271-9500</phone>
      <email>Elizabeth.Harders@uphs.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherri Mosovsky</last_name>
      <phone>412-692-4659</phone>
      <email>Slmst80@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Harper</last_name>
      <phone>615-322-2538</phone>
      <email>kelly.a.harper@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Doudova</last_name>
      <phone>801-581-3818</phone>
      <email>mariana.doudova@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Maupin</last_name>
      <phone>434-982-6961</phone>
      <email>klm8a@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521-37.</citation>
    <PMID>17612949</PMID>
  </reference>
  <reference>
    <citation>Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov Disord. 2007 Jul 30;22(10):1495-1498. doi: 10.1002/mds.21542.</citation>
    <PMID>17516492</PMID>
  </reference>
  <reference>
    <citation>Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. J Clin Psychiatry. 1999 Nov;60(11):799-808; quiz 809.</citation>
    <PMID>10584776</PMID>
  </reference>
  <reference>
    <citation>Gallin PF, Terman M, Remé CE, Rafferty B, Terman JS, Burde RM. Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. Am J Ophthalmol. 1995 Feb;119(2):202-10.</citation>
    <PMID>7832227</PMID>
  </reference>
  <reference>
    <citation>Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017 Apr 1;74(4):411-418. doi: 10.1001/jamaneurol.2016.5192.</citation>
    <PMID>28241159</PMID>
  </reference>
  <reference>
    <citation>Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B, Hülsmann J, Martinez-Martin P, Chaudhuri KR. Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011 Mar;26(4):644-52. doi: 10.1002/mds.23476. Epub 2011 Feb 10.</citation>
    <PMID>21312275</PMID>
  </reference>
  <reference>
    <citation>Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005 Jan;11(1):49-55.</citation>
    <PMID>15619463</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Aleksandar Videnovic, MD</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Light therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This trial will follow the NINDS policy for data sharing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

